February 26, 2020 / 1:22 PM / a month ago

BRIEF-Seelos Therapeutics Announces Additional Interim Data From Phase I Studies Of Intranasal Racemic Ketamine

Feb 26 (Reuters) - Seelos Therapeutics Inc:

* SEELOS THERAPEUTICS ANNOUNCES ADDITIONAL INTERIM DATA FROM PHASE I STUDIES OF INTRANASAL RACEMIC KETAMINE (SLS-002)

* SEELOS-INTERIM DATA FROM SLS-002-101,SLS-002-102 STUDIES DEMONSTRATED THAT DOSES OF 30MG, 60MG, 75MG & 90MG OF SLS-002 HAVE BEEN SAFE & WELL-TOLERATED

* SEELOS THERAPEUTICS INC - ADDITIONAL DATA FROM PHASE I OF SLS-002 EXPECTED TO BE RELEASED LATE IN Q1 AND EARLY IN Q2 OF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below